At the news
? NEUTRALIMPACT 5/10 8-K filed Jun 10, 2026 at 17:04 ET
Syndax Pharmaceuticals issued $250 million aggregate principal amount of 2.25% Convertible Senior Notes due 2031 in a private placement, generating net proceeds of approximately $243 million. The company plans to use the funds for general corporate purposes including R&D, commercialization, and business development. The notes are convertible into common stock at an initial rate of 40.3894 shares per $1,000 principal, with a maximum potential dilution of up to 13,631,400 shares.
- Issued $250 million aggregate principal amount of 2.25% Convertible Senior Notes due 2031
- Net proceeds of approximately $243 million after fees and expenses
- Initial conversion rate of 40.3894 shares per $1,000 principal amount of Notes
- Maximum of 13,631,400 shares of common stock may be issued upon conversion
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access